Tech Company Financing Transactions

Cecelia Health Funding Round

Endo Investors, Rittenhouse Ventures and Boston Millennia Partners participated in a $13 million Series B funding round for Cecelia Health. The round was announced on 8/14/2020.

Transaction Overview

Company Name
Cecelia Health
Announced On
8/14/2020
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Series B
Investors

Endo Investors (Lead Investor) (Eric Edidin)

Rittenhouse Ventures (Lead Investor)

Boston Millennia Partners (Dana Callow)

G100 Network (David Niles)

SustainVC

Proceeds Purpose
The funding will enable the company to accelerate and further scale the adoption of the company's technology enabled coaching and telemedicine solutions and expand Cecelia Health's digital health capabilities.

Company Information

Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
355 Lexington Ave.
New York, NY 10017
USA
Phone
(866) 411-0254
Website
www.ceceliahealth.com
Email Address
[email protected]
Overview
Cecelia Health, formerly Fit4D, is a high-growth, venture-backed health tech services company based in New York City. Founded in 2009 by David Weingard, the company has a proven track record of results including improving adherence to branded diabetes Rx by 20% and demonstrable reductions in A1C values.
Profile
Cecelia Health LinkedIn Company Profile
Social Media
Cecelia Health Company Twitter Account
Company News
Cecelia Health News
Facebook
Cecelia Health on Facebook
YouTube
Cecelia Health on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Weingard
  David Weingard LinkedIn Profile  David Weingard Twitter Account  David Weingard News  David Weingard on Facebook
Chief Financial Officer
Regina Reale
  Regina Reale LinkedIn Profile  Regina Reale Twitter Account  Regina Reale News  Regina Reale on Facebook
Chief Information Officer
Adam Normann
  Adam Normann LinkedIn Profile  Adam Normann Twitter Account  Adam Normann News  Adam Normann on Facebook
Chief Marketing Officer
Arnold Saperstein
  Arnold Saperstein LinkedIn Profile  Arnold Saperstein Twitter Account  Arnold Saperstein News  Arnold Saperstein on Facebook
Chief Operating Officer
Barry Kurland
  Barry Kurland LinkedIn Profile  Barry Kurland Twitter Account  Barry Kurland News  Barry Kurland on Facebook
Chief Technical Officer
Michael Plotkin
  Michael Plotkin LinkedIn Profile  Michael Plotkin Twitter Account  Michael Plotkin News  Michael Plotkin on Facebook
Vice President
Teresa McArthur
  Teresa McArthur LinkedIn Profile  Teresa McArthur Twitter Account  Teresa McArthur News  Teresa McArthur on Facebook
VP - Bus. Development
Michael Balsam
  Michael Balsam LinkedIn Profile  Michael Balsam Twitter Account  Michael Balsam News  Michael Balsam on Facebook
VP - Customer Service
Rozan Abdulrahman
  Rozan Abdulrahman LinkedIn Profile  Rozan Abdulrahman Twitter Account  Rozan Abdulrahman News  Rozan Abdulrahman on Facebook
VP - Human Resources
Dwight Scott
  Dwight Scott LinkedIn Profile  Dwight Scott Twitter Account  Dwight Scott News  Dwight Scott on Facebook
VP - Marketing
Vic Baldry
  Vic Baldry LinkedIn Profile  Vic Baldry Twitter Account  Vic Baldry News  Vic Baldry on Facebook
VP - Product Management
Mo Harrim
  Mo Harrim LinkedIn Profile  Mo Harrim Twitter Account  Mo Harrim News  Mo Harrim on Facebook
VP - Sales
Daniel Dwyer
  Daniel Dwyer LinkedIn Profile  Daniel Dwyer Twitter Account  Daniel Dwyer News  Daniel Dwyer on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/14/2020: Elisity venture capital transaction
Next: 8/14/2020: Mission Bio venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.